Marina Biotech Stock Price, News & Analysis (OTCMKTS:MRNA)

$2.10 0.10 (5.00 %)
(As of 12/14/2017 04:00 PM ET)
Previous Close$2.10
Today's Range$2.10 - $2.10
52-Week Range$1.21 - $5.00
Volume462 shs
Average Volume5,262 shs
Market Capitalization$21.36 million
P/E RatioN/A
Dividend YieldN/A
Beta1.19

About Marina Biotech (OTCMKTS:MRNA)

Marina Biotech, Inc. is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases. The Company's pipeline includes CEQ508, a product in clinical development for the treatment of Familial Adenomatous Polyposis (FAP), and preclinical programs for the treatment of type 1 myotonic dystrophy (DM1) and Duchenne muscular dystrophy (DMD). It creates a range of therapeutics targeting coding and non-coding ribonucleic acid (RNA) through several mechanisms of action, such as RNA interference (RNAi), messenger RNA translational inhibition, exon skipping, microRNA (miRNA) replacement, miRNA inhibition and steric blocking in order to modulate gene expression either up or down depending on the specific mechanism of action. It has two liposomal-based delivery platforms: SMARTICLES, and the platform, which utilizes amino-based liposomal delivery technology and incorporates a molecule, Di-Alkylated Amino Acid (DiLA2).

Receive MRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:MRNA
CUSIPN/A
Phone626-964-5788

Debt

Debt-to-Equity RatioN/A
Current Ratio0.01%
Quick Ratio0.01%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$680,000.00
Price / Sales32.49
Cash FlowN/A
Price / CashN/A
Book Value$0.36 per share
Price / Book5.83

Profitability

Trailing EPSN/A
Net Income$-830,000.00
Net MarginsN/A
Return on Equity-139.40%
Return on Assets-59.40%

Miscellaneous

Employees4
Outstanding Shares10,520,000

Marina Biotech (OTCMKTS:MRNA) Frequently Asked Questions

What is Marina Biotech's stock symbol?

Marina Biotech trades on the OTCMKTS under the ticker symbol "MRNA."

How were Marina Biotech's earnings last quarter?

Marina Biotech Inc. (OTCMKTS:MRNA) issued its quarterly earnings data on Monday, November, 21st. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.05 million for the quarter. View Marina Biotech's Earnings History.

When will Marina Biotech make its next earnings announcement?

Marina Biotech is scheduled to release their next quarterly earnings announcement on Friday, March, 30th 2018. View Earnings Estimates for Marina Biotech.

Who are some of Marina Biotech's key competitors?

Who are Marina Biotech's key executives?

Marina Biotech's management team includes the folowing people:

  • Vuong Trieu Ph.D., Executive Chairman of the Board (Age 51)
  • Joseph W. Ramelli, Chief Executive Officer, Secretary (Age 48)
  • Amit Shah, Chief Financial Officer
  • Mihir Munsif, Chief Operating Officer (Age 54)
  • Larn Hwang Ph.D., Chief Scientific Officer (Age 54)
  • Erik Emerson, Chief Commercial Officer
  • Peter D. Weinstein Ph.D., Chief Legal Officer
  • Isaac Blech, Director (Age 67)
  • Philippe Calais Ph.D, Director

How do I buy Marina Biotech stock?

Shares of Marina Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Marina Biotech's stock price today?

One share of Marina Biotech stock can currently be purchased for approximately $2.10.

How big of a company is Marina Biotech?

Marina Biotech has a market capitalization of $21.36 million and generates $680,000.00 in revenue each year. Marina Biotech employs 4 workers across the globe.

How can I contact Marina Biotech?

Marina Biotech's mailing address is 17870 CASTLETON STREET SUITE 250, CITY OF INDUSTRY CA, 91748. The biotechnology company can be reached via phone at 626-964-5788 or via email at [email protected]


MarketBeat Community Rating for Marina Biotech (MRNA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  38 (Vote Outperform)
Underperform Votes:  25 (Vote Underperform)
Total Votes:  63
MarketBeat's community ratings are surveys of what our community members think about Marina Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Marina Biotech (OTCMKTS:MRNA) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Marina Biotech (OTCMKTS:MRNA) Earnings History and Estimates Chart

Earnings by Quarter for Marina Biotech (OTCMKTS:MRNA)

Marina Biotech (OTCMKTS MRNA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/30/2018        
11/21/2016Q3 2016($0.05)$0.05 millionViewN/AView Earnings Details
11/17/2014Q3 14($0.28)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Marina Biotech (OTCMKTS:MRNA) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Marina Biotech (OTCMKTS:MRNA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Marina Biotech (OTCMKTS MRNA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 50.00%
Insider Trades by Quarter for Marina Biotech (OTCMKTS:MRNA)

Marina Biotech (OTCMKTS MRNA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/9/2017Vuong TrieuChairmanBuy10,000$0.39$3,900.00View SEC Filing  
6/7/2017Vuong TrieuChairmanBuy22,500$0.39$8,775.00View SEC Filing  
4/6/2017Joseph W RamelliCEOBuy35,500$0.39$13,845.00View SEC Filing  
4/5/2017Joseph W RamelliCEOBuy97,550$0.31$30,240.50View SEC Filing  
2/6/2017Vuong TrieuChairmanBuy862,068$0.29$249,999.72View SEC Filing  
4/16/2014Joseph W RamelliDirectorBuy26,300$0.76$19,988.00View SEC Filing  
2/10/2014Cashman Llp PryorMajor ShareholderSell108,041$0.99$106,960.59View SEC Filing  
10/4/2013Cashman Llp PryorMajor ShareholderSell100,000$0.25$25,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Marina Biotech (OTCMKTS MRNA) News Headlines

Source:
DateHeadline
Marina Biotech (MRNA) Lowered to Sell at ValuEngineMarina Biotech (MRNA) Lowered to Sell at ValuEngine
www.americanbankingnews.com - December 3 at 6:30 AM
Marina Biotech Appoints Isaac Blech to its Board of DirectorsMarina Biotech Appoints Isaac Blech to its Board of Directors
finance.yahoo.com - November 27 at 3:45 PM
Marina Biotech Appoints Chief Legal Officer to Support Legal, Transactional and Intellectual Property Portfolio InitiativesMarina Biotech Appoints Chief Legal Officer to Support Legal, Transactional and Intellectual Property Portfolio Initiatives
finance.yahoo.com - October 20 at 6:29 AM
Marina Biotech Appoints Amit Shah as Chief Financial OfficerMarina Biotech Appoints Amit Shah as Chief Financial Officer
finance.yahoo.com - October 5 at 8:59 AM
Windlas Healthcare Invests $2 Million in Working Capital to Support Marina Biotech’s Manufacturing InitiativesWindlas Healthcare Invests $2 Million in Working Capital to Support Marina Biotech’s Manufacturing Initiatives
finance.yahoo.com - August 21 at 8:06 PM
Marina Biotech Announces 1-for-10 Reverse Stock Split in Preparation for Proposed Up-Listing of its Common Stock to the NASDAQ Capital MarketMarina Biotech Announces 1-for-10 Reverse Stock Split in Preparation for Proposed Up-Listing of its Common Stock to the NASDAQ Capital Market
finance.yahoo.com - August 3 at 5:57 AM
Marina Biotech Announces Binding Letter of Intent for the Sale of its DiLA2 Delivery PlatformMarina Biotech Announces Binding Letter of Intent for the Sale of its DiLA2 Delivery Platform
finance.yahoo.com - July 26 at 1:11 AM
Marina Biotech Acquires DyrctAxess™ Technology Platform to Support Sales and Marketing of Prestalia®Marina Biotech Acquires DyrctAxess™ Technology Platform to Support Sales and Marketing of Prestalia®
finance.yahoo.com - July 25 at 4:06 AM
Marina Biotech up 11% on SMARTICLES license dealMarina Biotech up 11% on SMARTICLES license deal
seekingalpha.com - July 20 at 1:44 AM
Marina Biotech Announces a License Agreement to SMARTICLES and CRN platforms for Antisense DNA therapeuticsMarina Biotech Announces a License Agreement to SMARTICLES and CRN platforms for Antisense DNA therapeutics
finance.yahoo.com - July 20 at 1:44 AM
Marina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive ChairmanMarina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive Chairman
finance.yahoo.com - July 5 at 8:41 AM
MARINA BIOTECH, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Change in Directors or Principal OffMARINA BIOTECH, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Change in Directors or Principal Off
biz.yahoo.com - February 14 at 8:15 PM
Marina Biotech Announces a License Agreement to SMARTICLESMarina Biotech Announces a License Agreement to SMARTICLES
us.rd.yahoo.com - February 7 at 7:58 PM
10:28 am Marina Biotech (thinly-traded) entered into a license agreement regarding its SMARTICLES platform; could receive up to $90 mln in success based milestones10:28 am Marina Biotech (thinly-traded) entered into a license agreement regarding its SMARTICLES platform; could receive up to $90 mln in success based milestones
us.rd.yahoo.com - February 7 at 7:58 PM
MARINA BIOTECH, INC. Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Statements aMARINA BIOTECH, INC. Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Statements a
biz.yahoo.com - January 28 at 1:50 AM
MARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other EventsMARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
biz.yahoo.com - December 14 at 7:19 PM
MARINA BIOTECH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or DisMARINA BIOTECH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Dis
biz.yahoo.com - November 18 at 5:51 PM
Marina Biotech (MRNA) to Merge with IthenaPharmaMarina Biotech (MRNA) to Merge with IthenaPharma
www.streetinsider.com - November 16 at 9:56 AM
MARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal OfficersMARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - August 1 at 9:17 AM
MARINA BIOTECH, INC. Files SEC form 8-K, Other EventsMARINA BIOTECH, INC. Files SEC form 8-K, Other Events
biz.yahoo.com - June 24 at 9:17 AM
MARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitsMARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
biz.yahoo.com - June 2 at 9:58 AM

SEC Filings

Marina Biotech (OTCMKTS:MRNA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Marina Biotech (OTCMKTS:MRNA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Marina Biotech (OTCMKTS MRNA) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.